The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Oncology Hematology Group of South Florida
Miami, Florida, United States
Florida Cancer Institute
New Port Richey, Florida, United States
Objective Response Rate in subjects with NSCLC
Time frame: 1 year
Time to Tumor Progression (TTP)
Time frame: 1 year
Survival
Time frame: 2 years
Toxicities associated with treatment administration
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Chicago Medical Center
Chicago, Illinois, United States
University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States
Oncology & Hematology Associates of Kansas City, PA
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Albany Regional Cancer Center
Albany, New York, United States
Raleigh Hematology Oncology
Cary, North Carolina, United States
Dayton Oncology and Hematology
Kettering, Ohio, United States
Cancer Care Associates
Oklahoma City, Oklahoma, United States
...and 7 more locations